Basel Medical vs SBC Medical
BMGL and SBC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMGL and SBC compare
Basel Medical grew revenue faster over the last twelve months (45.2% versus −6.9% for SBC Medical).
SBC Medical keeps more of each dollar of sales as profit, with a net margin of 28.0% compared with −4.5% at Basel Medical.
SBC Medical scores higher on the StockData Score (12 against 3 for Basel Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMGL | SBC |
|---|---|---|
| Size and price | ||
| Market cap | – | $539M |
| Share price | $0.684 | $5.24 |
| Change, 1 year | −96.1% | 53.2% |
| Beta (5Y) | −0.01 | 0.44 |
| Employees | 81 | 863 |
| StockData Score | ||
| Total score | 3 | 12 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 11.1× |
| P/S | – | 3.1× |
| P/B | – | 2.0× |
| EV/EBITDA | – | 5.4× |
| P/FCF | – | 8.7× |
| FCF yield | – | 11.5% |
| Fair value | – | $8.64 |
| Margin of safety | – | 39.3% |
| Growth | ||
| Revenue growth (TTM) | 45.2% (better) | −6.9% |
| Net income growth (TTM) | – | 47.1% |
| EPS growth (TTM) | – | 46.9% |
| Profitability | ||
| Gross margin | – | 71.9% |
| Operating margin | – | 37.3% |
| Net margin | −4.5% | 28.0% (better) |
| FCF margin | −5.4% | 35.3% (better) |
| Return on equity | – | 19.3% |
| Return on invested capital | – | 50.7% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | – | −2.69 |
| Interest coverage | – | 195× |
| Current ratio | 1.23 | 3.31 (better) |
| Altman Z-score | – | 4.95 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 8.3% |
| Held by insiders | – | 82.0% |
| Insider net buying, 12 months | – | −$20.1M |
Go deeper
- BMGL stock overview
- BMGL income statement
- BMGL valuation and score
- SBC stock overview
- SBC income statement
- SBC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.